ERBB2 and cancer: Interestingly, we found that mutations in this region of EGFR, BRAF, ERBB2, and MAP2K1 were mutually exclusive (Figure 1c), which is consistent with a previous report (Arcila et al., 2015) that suggested one driver mutation is sufficient cancer initiation or development.